ITOS vs. LXEO, FATE, ALVO, ADPT, REPL, TSHA, EDIT, CCCC, TCRX, and VYGR Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Alvotech (ALVO), Adaptive Biotechnologies (ADPT), Replimune Group (REPL), Taysha Gene Therapies (TSHA), Editas Medicine (EDIT), C4 Therapeutics (CCCC), TScan Therapeutics (TCRX), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Lexeo Therapeutics (NASDAQ:LXEO ) and iTeos Therapeutics (NASDAQ:ITOS ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
Lexeo Therapeutics' return on equity of -23.15% beat iTeos Therapeutics' return on equity.
Lexeo Therapeutics presently has a consensus target price of $20.80, indicating a potential upside of 50.18%. iTeos Therapeutics has a consensus target price of $31.00, indicating a potential upside of 71.75%. Given Lexeo Therapeutics' higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Lexeo Therapeutics.
Lexeo Therapeutics has higher earnings, but lower revenue than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, iTeos Therapeutics had 11 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 16 mentions for iTeos Therapeutics and 5 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.87 beat iTeos Therapeutics' score of 0.05 indicating that iTeos Therapeutics is being referred to more favorably in the news media.
60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 10.2% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
iTeos Therapeutics received 24 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 73.17% of users gave iTeos Therapeutics an outperform vote.
Summary iTeos Therapeutics beats Lexeo Therapeutics on 10 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
iTeos Therapeutics Competitors List
Related Companies and Tools
